

FEBS Workshop 2018 - Emerging issues of breast cancer research: tumour heterogeneity, immunotherapy, and cellular metabolism

Wednesday, 2018/4/4

09:45 - 10:15 HAS RCNS - Lecture Hall
Arrival and Registration Arrival and Registration

10:15 - 10:45 HAS RCNS - Lecture Hall
Opening Session Opening Session

10:15 - 10:35 **Member In Charge presentation**

Ivan G. Ivanov (Bulgarian Academy of Sciences, Sofia, Bulgaria)

10:15 - 10:20 **Welcome message by László Buday, Director of the Institute of Enzymology, Research Centre of Natural Sciences, Hungarian Academy of Sciences**

László Buday (HAS, RCNS, Budapest, Hungary)

10:15 - 10:20 **Opening of the scientific meeting by Balázs Gyórfy**

Balázs Gyórfy (HAS, RCNS, Budapest, Hungary)

10:45 - 13:00 HAS RCNS - Lecture Hall
Tumour heterogeneity - Session 1 Lectures
Chair: Thomas Karn (DE)

10:45 - 11:30 **The importance of retaining cell fate differentiation function in tumors.**

Saraswati Sukumar (Johns Hopkins Medicine, Baltimore, USA)

11:30 - 12:15 **Genomic data and new biomarkers in breast cancer.**

Balázs Gyórfy (HAS, RCNS, Budapest, Hungary)

12:15 - 13:00 **Telomerase drives tumor cell heterogeneity: Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor.**

Michael Lisanti (University of Salford, Manchester, UK)

13:00 - 14:00 HAS RCNS - Restaurant
Lunch Break Break

14:00 - 16:25 HAS RCNS - Lecture Hall
Tumour heterogeneity - Session 2 Lectures
Chair: Saraswati Sukumar (US)

14:00 - 14:45 **Morphological and molecular heterogeneity in breast cancer.**

Attila Marcell Szász (II. Department of Pathology, Semmelweis University, Budapest, Hungary)

14:00 - 14:10 **Proteomics analysis to assess the role of mitochondria in BRCA1-mediated breast tumorigenesis**

Domenica Scumaci (University Catanzaro, Italy)

14:00 - 14:45 **Who's fighting whom in breast cancer? Relationships between tumor immunoediting and clonal heterogeneity.**

Thomas Karn (Goethe University, Frankfurt am Main, Germany)

14:00 - 14:45 **Her2 heterogeneity in invasive breast carcinoma.**

Janina Kulka (II. Department of Pathology, Semmelweis University, Budapest, Hungary)

16:25 - 18:00 HAS RCNS - Lecture Hall
Poster Session 1 Poster Sessions
Chairs: Michael Lisanti (GB) Thomas Karn (DE)

FEBS Workshop 2018 - Emerging issues of breast cancer research: tumour heterogeneity, immunotherapy, and cellular metabolism

18:00 - 20:00 HAS RCNS - Restaurant
Dinner

Break

Thursday, 2018/4/5

09:00 - 11:15 HAS RCNS - Lecture Hall

Immunotherapy - Session 1

Chair: Giampaolo Bianchini (IT)

Lectures

09:00 - 09:45 **Clinical development of trastuzumab biosimilars.**
Francisco J. Esteva (NYU Langone Medical Center, New York, USA)

09:00 - 09:45 **Road Intersection of Innate & Adaptive Immunity in breast cancer.**
Libero Santarpia (Humanitas Clinical and Research Center, Milan, Italy)

09:00 - 09:45 **How to make the tumor microenvironment great again.**
Lajos Pusztai (Yale School of Medicine, New Haven, USA)

11:15 - 11:25 HAS RCNS - Lecture Hall

Coffee Break

Break

11:25 - 12:55 HAS RCNS - Lecture Hall

Immunotherapy - Session 2

Chair: Lajos Pusztai (US)

Lectures

11:25 - 12:10 **Truth is in the blood: detecting breast cancer heterogeneity with CTC and ctDNA.**
Huseyin Baloglu (Anadolu Medical Center, Gebze, Turkey)

11:25 - 12:10 **Resistance mechanism in triple negative breast cancer.**
Cornelia Liedtke (Department of Obstetrics and Gynecology, University of Lübeck, Lübeck, Germany)

12:55 - 13:40 HAS RCNS - Restaurant

Lunch Break

Break

13:40 - 16:40 HAS RCNS - Lecture Hall

Immunotherapy - Session 3

Chair: Libero Santarpia (IT)

Lectures

13:40 - 14:25 **The Optimal Treatment Of the Axilla.**
Ákos Sávolt (National Institute of Oncology, Budapest, Hungary)

13:40 - 14:25 **DNA repair pathway aberrations and breast cancer therapy - how close are we to the best possible exploitation.**
Zoltán Szállási (Danish Technical University, Copenhagen, Denmark)

13:40 - 14:25 **Key interactions between HER2-targeted monoclonal antibodies and immune system.**
Giampaolo Bianchini (Ospedale San Raffaele, Milan, Italy)

13:40 - 14:25 **The Current State of Immuno-Oncology.**
Orsolya Dohán (Department of Oncology, Semmelweis University, Budapest, Hungary)

FEBS Workshop 2018 - Emerging issues of breast cancer research: tumour heterogeneity, immunotherapy, and cellular metabolism

16:40 - 16:50 HAS RCNS - Lecture Hall
Coffee Break Break

16:50 - 17:30 HAS RCNS - Lecture Hall
Poster Session 2 Poster Sessions
Chairs: Christine Desmedt (BE) Ubaldo Martinez Outschoorn (US)

17:30 - 18:30 HAS RCNS - Restaurant
Dinner Break

Friday, 2018/4/6

09:00 - 10:30 HAS RCNS - Lecture Hall
Metabolism - Session 1 Lectures
Chair: Ubaldo Martinez Outschoorn (US)

09:00 - 09:45 **Breast Cancer Genomic Markers in the Post-First Generation Era.**
Takayuki Iwamoto (Okayama University, Okayama, Japan)

09:00 - 09:45 **Intratumor, Clonal and Phenotypic Heterogeneity in Breast Cancer: Characterization and Implications**
Christos Hatzis (Yale School of Medicine, New Haven, USA)

10:30 - 10:40 HAS RCNS - Lecture Hall
Coffee Break Break

10:40 - 12:55 HAS RCNS - Lecture Hall
Metabolism - Session 2 Lectures
Chair: Takayuki Iwamoto (JP)

10:40 - 11:25 **Phylogenetic reconstruction of breast cancer progression.**
Christine Desmedt (Institut Jules Bordet, Brussels, Belgium)

10:40 - 11:25 **The structural biochemist's view on cancer: what goes wrong and how to mend it.**
Attila Reményi (HAS, RCNS, Budapest, Hungary)

10:40 - 11:25 **Targeting Tumor Metabolic Ecosystems in Breast Cancer.**
Ubaldo Martinez Outschoorn (Thomas Jefferson University, Philadelphia, USA)

12:55 - 13:40 HAS RCNS - Restaurant
Lunch Break Break

13:40 - 15:10 HAS RCNS - Lecture Hall
Metabolism - Session 3 Lectures
Chair: Christos Hatzis (US)

13:40 - 14:25 **Combination therapy and drug resistance in triple negative breast cancer.**
Sima Lev (Weizmann Institute of Science, Rehovot, Israel)

14:25 - 14:45 **A novel mitochondrial inhibitor for eradicating breast cancer stem cells.**
Bela Ozsvari (University of Salford, Manchester, UK)

FEBS Workshop 2018 - Emerging issues of breast cancer research: tumour heterogeneity, immunotherapy, and cellular metabolism

14:45 - 15:10 **Mitochondrial "power" drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer.**
Marco Fiorillo (University of Salford, Manchester, UK)

15:10 - 15:55 HAS RCNS - Lecture Hall
Exam (only for Ph.D. students registered in NEPTUN)

Closing Session

15:55 - 16:00 HAS RCNS - Lecture Hall
Closing of the course

Closing Session